Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine

E. B. Belknap, L. M. Walters, Clayton L Kelling, V. K. Ayers, J. Norris, J. McMillen, C. Hayhow, M. Cochran, D. N. Reddy, J. Wright, J. K. Collins

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The efficacy and safety of a gene-deleted bovine herpesvirus-1 (BHV-1) vaccine was determined in a bovine herpesvirus challenge trial in calves. Three different doses of the vaccine were administered intramuscularly at 105, 106 and 107 PFU/ml and compared to a commercial vaccine and non vaccinated control calves. Challenge was performed by intranasal aerosolization with the Cooper strain of BHV-1 (3 x 104 PFU/ml). The non- vaccinated calves shed significantly (P < 0.05) more virus than all other groups on days 4, 8 and 10 post challenge. By day 14 post challenge, antibody titers for BHV-1 of calves vaccinated with 107 PFU/ml were significantly (P < 0.05) higher than the commercial or non-vaccinated calves. Clinical scores of non-vaccinated calves were significantly (P < 0.05) higher than all other groups on days 4-14 post challenge. With both radioimmunoprecipitation and competitive enzyme-linked immunosorbent assays (C-ELISA), calves in the gene- deleted vaccine groups mounted comparable specific responses against gB, gC and gD post vaccination as calves in the commercial vaccine group, but in a dose dependent manner. These data suggest that the gene-deleted BHV-1 vaccine tested may be used as an effective vaccine in controlling BHV-1 infections.

Original languageEnglish (US)
Pages (from-to)2297-2305
Number of pages9
JournalVaccine
Volume17
Issue number18
DOIs
StatePublished - May 4 1999

Fingerprint

Herpesvirus Vaccines
Bovine Herpesvirus 1
Bovine herpesvirus 1
Vaccines
immune response
calves
vaccines
Genes
genes
Herpesviridae Infections
Herpesviridae
Vaccination
Enzyme-Linked Immunosorbent Assay
Viruses
Safety
dosage
Antibodies
vaccination
enzyme-linked immunosorbent assay

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Belknap, E. B., Walters, L. M., Kelling, C. L., Ayers, V. K., Norris, J., McMillen, J., ... Collins, J. K. (1999). Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine. Vaccine, 17(18), 2297-2305. https://doi.org/10.1016/S0264-410X(98)00466-6

Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine. / Belknap, E. B.; Walters, L. M.; Kelling, Clayton L; Ayers, V. K.; Norris, J.; McMillen, J.; Hayhow, C.; Cochran, M.; Reddy, D. N.; Wright, J.; Collins, J. K.

In: Vaccine, Vol. 17, No. 18, 04.05.1999, p. 2297-2305.

Research output: Contribution to journalArticle

Belknap, EB, Walters, LM, Kelling, CL, Ayers, VK, Norris, J, McMillen, J, Hayhow, C, Cochran, M, Reddy, DN, Wright, J & Collins, JK 1999, 'Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine', Vaccine, vol. 17, no. 18, pp. 2297-2305. https://doi.org/10.1016/S0264-410X(98)00466-6
Belknap, E. B. ; Walters, L. M. ; Kelling, Clayton L ; Ayers, V. K. ; Norris, J. ; McMillen, J. ; Hayhow, C. ; Cochran, M. ; Reddy, D. N. ; Wright, J. ; Collins, J. K. / Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine. In: Vaccine. 1999 ; Vol. 17, No. 18. pp. 2297-2305.
@article{94e63a4a1bcf437b855a10896f17e0dd,
title = "Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine",
abstract = "The efficacy and safety of a gene-deleted bovine herpesvirus-1 (BHV-1) vaccine was determined in a bovine herpesvirus challenge trial in calves. Three different doses of the vaccine were administered intramuscularly at 105, 106 and 107 PFU/ml and compared to a commercial vaccine and non vaccinated control calves. Challenge was performed by intranasal aerosolization with the Cooper strain of BHV-1 (3 x 104 PFU/ml). The non- vaccinated calves shed significantly (P < 0.05) more virus than all other groups on days 4, 8 and 10 post challenge. By day 14 post challenge, antibody titers for BHV-1 of calves vaccinated with 107 PFU/ml were significantly (P < 0.05) higher than the commercial or non-vaccinated calves. Clinical scores of non-vaccinated calves were significantly (P < 0.05) higher than all other groups on days 4-14 post challenge. With both radioimmunoprecipitation and competitive enzyme-linked immunosorbent assays (C-ELISA), calves in the gene- deleted vaccine groups mounted comparable specific responses against gB, gC and gD post vaccination as calves in the commercial vaccine group, but in a dose dependent manner. These data suggest that the gene-deleted BHV-1 vaccine tested may be used as an effective vaccine in controlling BHV-1 infections.",
author = "Belknap, {E. B.} and Walters, {L. M.} and Kelling, {Clayton L} and Ayers, {V. K.} and J. Norris and J. McMillen and C. Hayhow and M. Cochran and Reddy, {D. N.} and J. Wright and Collins, {J. K.}",
year = "1999",
month = "5",
day = "4",
doi = "10.1016/S0264-410X(98)00466-6",
language = "English (US)",
volume = "17",
pages = "2297--2305",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "18",

}

TY - JOUR

T1 - Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine

AU - Belknap, E. B.

AU - Walters, L. M.

AU - Kelling, Clayton L

AU - Ayers, V. K.

AU - Norris, J.

AU - McMillen, J.

AU - Hayhow, C.

AU - Cochran, M.

AU - Reddy, D. N.

AU - Wright, J.

AU - Collins, J. K.

PY - 1999/5/4

Y1 - 1999/5/4

N2 - The efficacy and safety of a gene-deleted bovine herpesvirus-1 (BHV-1) vaccine was determined in a bovine herpesvirus challenge trial in calves. Three different doses of the vaccine were administered intramuscularly at 105, 106 and 107 PFU/ml and compared to a commercial vaccine and non vaccinated control calves. Challenge was performed by intranasal aerosolization with the Cooper strain of BHV-1 (3 x 104 PFU/ml). The non- vaccinated calves shed significantly (P < 0.05) more virus than all other groups on days 4, 8 and 10 post challenge. By day 14 post challenge, antibody titers for BHV-1 of calves vaccinated with 107 PFU/ml were significantly (P < 0.05) higher than the commercial or non-vaccinated calves. Clinical scores of non-vaccinated calves were significantly (P < 0.05) higher than all other groups on days 4-14 post challenge. With both radioimmunoprecipitation and competitive enzyme-linked immunosorbent assays (C-ELISA), calves in the gene- deleted vaccine groups mounted comparable specific responses against gB, gC and gD post vaccination as calves in the commercial vaccine group, but in a dose dependent manner. These data suggest that the gene-deleted BHV-1 vaccine tested may be used as an effective vaccine in controlling BHV-1 infections.

AB - The efficacy and safety of a gene-deleted bovine herpesvirus-1 (BHV-1) vaccine was determined in a bovine herpesvirus challenge trial in calves. Three different doses of the vaccine were administered intramuscularly at 105, 106 and 107 PFU/ml and compared to a commercial vaccine and non vaccinated control calves. Challenge was performed by intranasal aerosolization with the Cooper strain of BHV-1 (3 x 104 PFU/ml). The non- vaccinated calves shed significantly (P < 0.05) more virus than all other groups on days 4, 8 and 10 post challenge. By day 14 post challenge, antibody titers for BHV-1 of calves vaccinated with 107 PFU/ml were significantly (P < 0.05) higher than the commercial or non-vaccinated calves. Clinical scores of non-vaccinated calves were significantly (P < 0.05) higher than all other groups on days 4-14 post challenge. With both radioimmunoprecipitation and competitive enzyme-linked immunosorbent assays (C-ELISA), calves in the gene- deleted vaccine groups mounted comparable specific responses against gB, gC and gD post vaccination as calves in the commercial vaccine group, but in a dose dependent manner. These data suggest that the gene-deleted BHV-1 vaccine tested may be used as an effective vaccine in controlling BHV-1 infections.

UR - http://www.scopus.com/inward/record.url?scp=0033522411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033522411&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(98)00466-6

DO - 10.1016/S0264-410X(98)00466-6

M3 - Article

C2 - 10403598

AN - SCOPUS:0033522411

VL - 17

SP - 2297

EP - 2305

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 18

ER -